{"gene":"BTK","run_date":"2026-06-09T22:02:45","timeline":{"discoveries":[{"year":1995,"finding":"Btk is required for normal B cell development in mice; targeted mutations eliminating the PH or kinase domain block Btk protein expression and result in reduced mature conventional B cells, severe B1 cell deficiency, serum IgM and IgG3 deficiency, and defective responses to B cell activators and thymus-independent type II antigens, proving that lack of Btk function produces the Xid phenotype.","method":"Gene targeting in embryonic stem cells (knockout of PH or kinase domain), RAG2-deficient blastocyst complementation, germline transmission, in vitro B cell activation assays, in vivo immunization","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — clean loss-of-function mouse models with defined cellular phenotypes, replicated across two distinct knockout alleles","pmids":["7552994"],"is_preprint":false},{"year":2001,"finding":"BLNK mediates Syk-dependent BTK activation in BCR signaling: in a reconstitution cell system, coexpression of BLNK allows Syk to phosphorylate Btk on tyrosine 551, enhancing Btk activity. This interaction requires the Btk SH2 domain binding to BLNK, and BCR-induced Btk phosphorylation and activation are significantly reduced in BLNK-deficient or Syk-deficient B cells.","method":"Reconstitution cell system (co-expression), site-specific phosphorylation assay (Y551), SH2 domain interaction studies, BLNK-deficient and Syk-deficient B cell analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution experiments combined with domain-specific interaction mapping and validation in knockout B cells","pmids":["11226282"],"is_preprint":false},{"year":2003,"finding":"BCR-controlled integrin alpha4beta1 (VLA-4)-mediated adhesion of B cells to VCAM-1 and fibronectin requires the consecutive activation of Lyn, Syk, PI3K, Btk, PLCgamma2, IP3R-mediated Ca2+ release, and PKC. Btk is positioned between PI3K and PLCgamma2 in this pathway, and Btk is also involved in control of integrin-mediated adhesion of pre-B cells. Cytoskeletal reorganization and integrin clustering are downstream consequences.","method":"Biochemical, pharmacological, and genetic dissection; knockout B cells; pharmacological inhibitors; adhesion assays to VCAM-1 and fibronectin","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — combined biochemical, pharmacological, and genetic approaches in multiple B cell models establishing pathway position","pmids":["14610042"],"is_preprint":false},{"year":2015,"finding":"BTK adopts an autoinhibited compact conformation similar to inactive c-Src and c-Abl, stabilized by its PH-TH module together with SH2 and SH3 domains. BTK is activated by membranes containing PIP3. Additionally, inositol hexakisphosphate (IP6), a soluble signaling molecule, activates BTK by inducing transient PH-TH dimerization that promotes transphosphorylation of the kinase domains; this IP6-mediated activation is unique to BTK among Tec-family kinases.","method":"X-ray crystallography, biochemical autoinhibition assays, lipid-binding assays, in vitro kinase activity assays, mutational analysis, sequence comparisons","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with multiple in vitro biochemical assays and mutagenesis establishing both autoinhibition mechanism and novel IP6-activation mode","pmids":["25699547"],"is_preprint":false},{"year":1999,"finding":"Btk constitutively associates with protein kinase C mu (PKCmu) via its PH-TH domain; both the kinase domain and the regulatory C1 region of PKCmu independently bind the Btk PH-TH domain. This interaction is not affected by BCR crosslinking, phorbol ester, or H2O2 stimulation.","method":"Co-immunoprecipitation, GST pulldown, transient overexpression of PKCmu deletion mutants and domain constructs in 293T cells","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP and GST pulldown with domain mapping in transfected cells, single lab, two orthogonal methods","pmids":["10561498"],"is_preprint":false},{"year":1998,"finding":"BTK functions as a dual-function regulator of apoptosis: it promotes radiation-induced apoptosis (at least partly by down-regulating anti-apoptotic STAT-3 activity in response to reactive oxygen species) but inhibits Fas-activated apoptosis by associating with the death receptor Fas and impairing its interaction with FADD, thereby preventing assembly of the pro-apoptotic DISC.","method":"Co-immunoprecipitation (BTK with Fas), functional apoptosis assays (radiation, Fas ligation), STAT-3 activity measurement","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP and functional apoptosis assays, single lab, two orthogonal methods supporting dual role","pmids":["9751072"],"is_preprint":false},{"year":2002,"finding":"Endogenous Btk and Akt physically interact in B cells (DT40 chicken B cells and human Nalm6 B cells) and this interaction is inducible by H2O2 stimulation. PI3K and Btk are involved in Akt phosphorylation following H2O2. Btk and Akt co-localize in the perinuclear region and membrane ruffles in COS-7 cells. Btk positively modulates both ERK and JNK phosphorylation downstream of PI3K.","method":"Co-immunoprecipitation of endogenous proteins, immunofluorescence co-localization, kinase phosphorylation assays, PI3K inhibitor studies","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — reciprocal co-IP of endogenous proteins with co-localization validation, single lab","pmids":["12054657"],"is_preprint":false},{"year":2012,"finding":"Btk is required for NK cell activation: Btk-deficient murine NK cells have decreased innate immune responses to the TLR3 ligand poly(I:C), with reduced IFN-γ, perforin, and granzyme-B expression and decreased cytotoxic activity. Btk promotes TLR3-triggered NK cell activation mainly by activating the NF-κB pathway. XLA patients with BTK deficiency also show reduced TLR3-triggered human NK cell activation.","method":"Btk-/- mouse NK cell functional assays, NF-κB pathway analysis, Btk inhibitor in vivo administration, adoptive transfer experiments, XLA patient NK cell assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout mouse model, pharmacological inhibition, adoptive transfer, and human patient validation, multiple orthogonal methods","pmids":["22589540"],"is_preprint":false},{"year":2016,"finding":"BTK transcriptionally upregulates BCL2 expression in mantle cell lymphoma through canonical NF-κB activation. BTK knockdown (by shRNA) downregulates a set of anti-apoptotic and proliferative genes including BCL2, BCL-XL, DAD1, BCL6, MYC, PIK3CA, and BAFF-R, as confirmed by RNA-seq analysis.","method":"BTK shRNA knockdown, RNA-seq, NF-κB reporter assays, tissue microarray correlation, in vitro and in vivo drug combination studies","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — shRNA knockdown with RNA-seq validation and mechanistic pathway confirmation, single lab","pmids":["27157620"],"is_preprint":false},{"year":2016,"finding":"BTK is a novel modulator of p53: BTK is induced in response to DNA damage and p53 activation, and BTK induction leads to p53 phosphorylation, establishing a positive feedback loop that increases p53 protein levels and enhances transactivation of p53 target genes. Inhibiting BTK reduced p53-dependent senescence and apoptosis.","method":"BTK induction by DNA damage, BTK inhibitor treatment, p53 phosphorylation assays, senescence and apoptosis functional assays, gene expression analysis","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition and overexpression with functional readouts (senescence, apoptosis) and molecular (p53 phosphorylation), single lab","pmids":["27630139"],"is_preprint":false},{"year":2021,"finding":"BTK directly interacts with NLRP3 in immune cells and phosphorylates four conserved tyrosine residues on NLRP3 upon inflammasome activation (demonstrated in vitro and in vivo). BTK promotes NLRP3 relocalization, oligomerization, ASC polymerization, and full inflammasome assembly, likely through charge neutralization upon modification of a polybasic linker that directs NLRP3 Golgi association. BTK-mediated NLRP3 tyrosine phosphorylation positively regulates IL-1β release.","method":"Co-immunoprecipitation, in vitro kinase assay, in vivo phosphorylation assay, NLRP3 localization studies, inflammasome assembly assays (ASC polymerization, oligomerization), IL-1β release measurement","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay plus in vivo validation, direct protein interaction, and multiple functional readouts (localization, oligomerization, IL-1β) in one study","pmids":["34554188"],"is_preprint":false},{"year":2021,"finding":"Low concentrations of BTK inhibitor ibrutinib (and acalabrutinib) selectively block CLEC-2-mediated platelet activation and tyrosine phosphorylation (including Syk and PLCγ2) in human platelets. BTK-deficient XLA patients also show abolished CLEC-2-mediated platelet activation. In contrast, GPVI-mediated platelet responses are only delayed (not abolished) at low inhibitor concentrations, with Syk phosphorylation preserved. This differential reflects a positive feedback role for Btk (along with ADP and thromboxane A2 via P2Y12 and TP receptors) that is present in CLEC-2 but not GPVI signaling in human platelets.","method":"Platelet activation assays (aggregation, tyrosine phosphorylation), BTK inhibitor dose-response studies, XLA patient platelet studies, in vivo thrombosis models in mice","journal":"Haematologica","confidence":"High","confidence_rationale":"Tier 2 / Strong — human patient (XLA) validation combined with pharmacological inhibition and in vivo mouse model, multiple orthogonal methods","pmids":["31949019"],"is_preprint":false},{"year":2022,"finding":"Kinase-dead BTK mutations C481F and C481Y confer ibrutinib resistance through a kinase-independent scaffold mechanism: upon BCR activation, BTK C481F/Y is phosphorylated at Y551 by Src family kinases, which then recruits HCK via its SH2 domain. Structural modeling suggests this binding disrupts an intramolecular autoinhibitory interaction in HCK, activating it. Activated HCK then phosphorylates PLCγ2, propagating BCR signaling and promoting clonogenic cell proliferation despite absence of BTK kinase activity.","method":"In vitro kinase assays (confirming loss of kinase activity), structural modeling, co-immunoprecipitation (BTK C481F/Y with HCK), phosphorylation assays (Y551, PLCγ2, NF-κB), clonogenic proliferation assays","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro kinase assays, structural modeling, co-IP, and multiple phosphorylation/functional readouts establishing kinase-independent scaffold mechanism","pmids":["35639855"],"is_preprint":false},{"year":2024,"finding":"Certain drug-resistant BTK mutations (including kinase-impaired forms) acquire novel protein-protein interactions that sustain BCR signaling independently of BTK enzymatic activity (oncogenic scaffold function). The BTK/IKZF1/3 degrader NX-2127 can bind and proteasomally degrade each mutant BTK proteoform, resulting in potent blockade of BCR signaling. Treatment of CLL patients with NX-2127 achieves >80% degradation of BTK.","method":"Enzymatic activity characterization of mutant BTK, protein-protein interaction studies, proteasomal degradation assays, BCR signaling blockade assays, clinical BTK degradation measurement","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — biochemical characterization of mutant enzymatic activities, interaction studies, degradation assays, and clinical proof-of-concept in patients","pmids":["38301010"],"is_preprint":false},{"year":2023,"finding":"Pirtobrutinib, a noncovalent BTK inhibitor, binds BTK with an extensive network of interactions to BTK and water molecules in the ATP-binding region with no direct interaction with C481, inhibiting both BTK and BTK C481 substitution mutants with similar potencies. Pirtobrutinib stabilizes BTK in a closed, inactive conformation (higher melting temperature than covalent BTKi-bound BTK in differential scanning fluorimetry) and prevents Y551 phosphorylation in the activation loop, unlike covalent BTKis.","method":"Structural studies (binding mode characterization), enzymatic assays, cell-based assays, differential scanning fluorimetry, Y551 phosphorylation assays, xenograft tumor growth studies","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural characterization with enzymatic, biophysical, and cellular validation across multiple orthogonal methods","pmids":["36796019"],"is_preprint":false},{"year":2024,"finding":"BTK is activated in human neutrophils upon fungal (Aspergillus) exposure in a TLR2-, Dectin-1-, and FcγR-dependent manner, triggering the oxidative burst. BTK inhibition selectively impaired neutrophil-mediated damage to Aspergillus hyphae, primary granule release, and the fungus-induced oxidative burst by abrogating NADPH oxidase subunit p40phox and GTPase RAC2 activation. Neutrophil-specific Btk deletion in mice enhanced aspergillosis susceptibility by impairing neutrophil function without affecting recruitment or lifespan.","method":"BTK activation assays in human neutrophils, BTK inhibitor studies, XLA patient neutrophil studies, neutrophil-specific Btk conditional knockout mice, p40phox and RAC2 activation assays, oxidative burst measurements, in vivo aspergillosis models","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — neutrophil-specific conditional KO mice, human patient (XLA) validation, pharmacological inhibition, and molecular mechanism (p40phox, RAC2) established","pmids":["38696257"],"is_preprint":false},{"year":2021,"finding":"In diffuse large B-cell lymphoma, acquired resistance to BTK inhibitor ibrutinib is epigenetically driven (in part by transcription factor TCF4), causing a phenotypic shift where GTPase RAC2 substitutes for BTK in the activation of PLCγ2 to sustain NF-κB activity. This RAC2-PLCγ2 interaction was also increased in CLL cells from patients with persistent or progressive disease on BTK inhibitor treatment.","method":"Ibrutinib resistance modeling in ABC-DLBCL cells, RNAi/genetic screens, RAC2 overexpression, PLCγ2 interaction studies, NF-κB reporter assays, patient CLL cell analysis","journal":"Blood cancer discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro resistance model with molecular pathway identification and human patient validation, single lab","pmids":["34778802"],"is_preprint":false},{"year":2020,"finding":"Ternary complex structures of BTK with the E3 ubiquitin ligase cIAP1 and bifunctional degrader compounds were characterized. Increased ternary complex stability or rigidity does not always correlate with increased degradation efficiency.","method":"Biochemical, biophysical, and structural studies (X-ray crystallography of ternary complexes), degradation efficiency assays","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures of ternary complexes with biochemical validation, single lab but rigorous methods","pmids":["33199914"],"is_preprint":false},{"year":2024,"finding":"TREM2 interacts with the phosphatase SHP1 to inhibit BTK-mediated fatty acid oxidation (FAO) in macrophages during sepsis. TREM2 deficiency in macrophages led to enhanced BTK-mediated FAO, reduced triglyceride accumulation, and improved sepsis outcomes; blockade of FAO abolished these protective effects.","method":"Co-immunoprecipitation (TREM2 with SHP1), Trem2 knockout mice, FAO rate measurement, triglyceride accumulation assays, BTK activity assays, survival studies","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP interaction, knockout model, and functional FAO assays, single lab","pmids":["39405126"],"is_preprint":false},{"year":2003,"finding":"BTK activates phosphatidylinositol-4-phosphate 5-kinase (PIP5K) downstream of BCR signaling, generating PI(4,5)P2 which serves as substrate for both PI3K and PLCγ, creating a positive feedback loop that amplifies BTK's signal.","method":"Review/commentary citing experimental data (Saito et al.) showing BTK-PIP5K activation and PI(4,5)P2 generation","journal":"Immunity","confidence":"Low","confidence_rationale":"Tier 3 / Weak — described in a commentary referencing primary data; mechanistic claim supported by cited experimental work but this abstract does not provide direct experimental details","pmids":["14614849"],"is_preprint":false}],"current_model":"BTK is a cytoplasmic Tec-family tyrosine kinase that is autoinhibited in a compact conformation (stabilized by PH-TH, SH2, and SH3 domains) and is activated downstream of BCR engagement via sequential Lyn-mediated phosphorylation at Y551 (facilitated by BLNK-scaffolded Syk), and also by PIP3-containing membranes or IP6-induced PH-TH dimerization; once active, BTK phosphorylates PLCγ2 to drive Ca2+ flux, NF-κB, and NFAT signaling, regulates integrin-mediated adhesion, directly phosphorylates and activates the NLRP3 inflammasome, modulates p53-dependent apoptosis/senescence, and in innate immune cells (NK cells, neutrophils) promotes TLR- and pattern-recognition receptor-triggered oxidative burst and cytokine production; drug-resistant kinase-dead BTK mutants can act as scaffolds recruiting and activating HCK to sustain BCR signaling independently of BTK kinase activity."},"narrative":{"mechanistic_narrative":"BTK is a cytoplasmic Tec-family tyrosine kinase that transduces B-cell receptor (BCR) signaling and is essential for normal B-cell development, its loss producing the murine Xid phenotype with B1-cell deficiency and impaired antibody responses [PMID:7552994]. The protein is held in an autoinhibited compact conformation stabilized by its PH-TH module together with the SH2 and SH3 domains, and is activated either at PIP3-containing membranes or, uniquely among Tec kinases, by inositol hexakisphosphate (IP6) that drives transient PH-TH dimerization and kinase transphosphorylation [PMID:25699547]. Within the BCR pathway, BLNK scaffolds Syk to phosphorylate BTK on Y551 via the BTK SH2 domain, and BCR-induced BTK activation is lost in BLNK- or Syk-deficient B cells [PMID:11226282]; downstream BTK occupies a position between PI3K and PLCγ2, where it controls integrin α4β1-mediated adhesion through PLCγ2/IP3R-driven Ca2+ release and cytoskeletal reorganization [PMID:14610042]. Through canonical NF-κB activation BTK drives transcription of anti-apoptotic and proliferative genes including BCL2 in mantle cell lymphoma [PMID:27157620], and it acts as a direct kinase of the NLRP3 inflammasome, phosphorylating conserved tyrosines to promote NLRP3 relocalization, oligomerization, ASC polymerization and IL-1β release [PMID:34554188]. BTK function extends to innate immunity, where it is required for TLR3-triggered NK-cell activation via NF-κB [PMID:22589540] and for fungus-induced neutrophil oxidative burst through p40phox and RAC2 activation [PMID:38696257]. Clinically important resistance to covalent BTK inhibitors arises through kinase-dead C481 scaffold mutants that recruit and activate HCK to sustain PLCγ2 signaling independently of BTK catalytic activity [PMID:35639855], a liability addressed by noncovalent inhibitors that bind outside C481 and lock BTK in a closed conformation [PMID:36796019] and by degraders that eliminate all mutant proteoforms [PMID:38301010].","teleology":[{"year":1995,"claim":"Established that BTK is genetically required for B-cell development, defining the loss-of-function phenotype and linking the gene to humoral immunodeficiency.","evidence":"Targeted knockout of PH or kinase domain in mice with B-cell activation and immunization assays","pmids":["7552994"],"confidence":"High","gaps":["Does not resolve the biochemical signaling step BTK occupies","Phenotype defined in mouse; human XLA correspondence inferred"]},{"year":1999,"claim":"Identified a constitutive PH-TH-mediated association between BTK and PKCmu, an early clue to BTK's protein interaction surface.","evidence":"Co-IP and GST pulldown with PKCmu domain constructs in 293T cells","pmids":["10561498"],"confidence":"Medium","gaps":["Functional consequence of the interaction undefined","Overexpression in transfected cells, single lab"]},{"year":2001,"claim":"Placed BTK activation within the BCR proximal cascade by showing BLNK scaffolds Syk to phosphorylate BTK on Y551, resolving how upstream kinases engage BTK.","evidence":"Reconstitution co-expression, Y551 phosphorylation assay, SH2 interaction mapping, BLNK/Syk-deficient B cells","pmids":["11226282"],"confidence":"High","gaps":["Does not address membrane recruitment via PH domain","Y551 dynamics under physiological BCR engagement not quantified"]},{"year":2003,"claim":"Positioned BTK between PI3K and PLCγ2 in integrin signaling, extending its role beyond Ca2+ flux to adhesion and cytoskeletal control.","evidence":"Genetic and pharmacological dissection of VLA-4-mediated B-cell adhesion to VCAM-1/fibronectin","pmids":["14610042"],"confidence":"High","gaps":["Direct BTK substrates in the adhesion pathway not pinpointed","Pre-B versus mature B-cell contributions only partially separated"]},{"year":2003,"claim":"Proposed a positive feedback loop in which BTK activates PIP5K to generate PI(4,5)P2 amplifying its own signal.","evidence":"Commentary citing primary BTK-PIP5K activation data","pmids":["14614849"],"confidence":"Low","gaps":["Claim drawn from a commentary, not direct experimental detail in this entry","Feedback stoichiometry and physiological relevance unquantified"]},{"year":2002,"claim":"Linked BTK to Akt/ERK/JNK signaling and oxidative stress responses, broadening BTK's downstream signaling reach.","evidence":"Reciprocal co-IP of endogenous BTK and Akt, co-localization, kinase assays with PI3K inhibitors in B-cell lines","pmids":["12054657"],"confidence":"Medium","gaps":["Direct versus indirect BTK-Akt interaction not distinguished","Single lab without genetic confirmation of the kinase relationships"]},{"year":1998,"claim":"Implicated BTK as a bidirectional regulator of apoptosis, promoting radiation-induced death yet inhibiting Fas-DISC assembly.","evidence":"Co-IP of BTK with Fas, radiation and Fas-ligation apoptosis assays, STAT-3 activity measurement","pmids":["9751072"],"confidence":"Medium","gaps":["Molecular basis of dual role not reconciled","Single lab, two orthogonal methods"]},{"year":2012,"claim":"Extended BTK function to innate immunity by showing it is required for TLR3-triggered NK-cell activation through NF-κB.","evidence":"Btk-/- mouse NK-cell assays, NF-κB analysis, adoptive transfer, XLA patient NK cells","pmids":["22589540"],"confidence":"High","gaps":["Direct BTK substrates in TLR3-NK signaling not identified","Mechanism of TLR3-to-BTK coupling unresolved"]},{"year":2015,"claim":"Defined the structural basis of BTK autoinhibition and revealed a BTK-unique IP6-induced PH-TH dimerization activation mode, resolving how BTK is switched on.","evidence":"X-ray crystallography, lipid-binding and kinase assays, mutagenesis, sequence comparisons","pmids":["25699547"],"confidence":"High","gaps":["Cellular concentration thresholds for IP6 activation not established","Integration of IP6 and PIP3 activation in vivo unclear"]},{"year":2016,"claim":"Connected BTK to a pro-survival transcriptional program, showing it upregulates BCL2 and other anti-apoptotic/proliferative genes via NF-κB in lymphoma.","evidence":"shRNA knockdown with RNA-seq, NF-κB reporter assays, tissue microarray in mantle cell lymphoma","pmids":["27157620"],"confidence":"Medium","gaps":["Direct versus indirect transcriptional effects not separated","Single lab"]},{"year":2016,"claim":"Identified BTK as a p53 modulator forming a DNA-damage-induced positive feedback loop that enhances p53-dependent senescence and apoptosis.","evidence":"BTK induction by DNA damage, inhibitor treatment, p53 phosphorylation and functional senescence/apoptosis assays","pmids":["27630139"],"confidence":"Medium","gaps":["Direct kinase relationship to p53 not biochemically defined","Single lab"]},{"year":2021,"claim":"Established BTK as a direct NLRP3 kinase, phosphorylating conserved tyrosines to drive inflammasome assembly and IL-1β release.","evidence":"Co-IP, in vitro and in vivo kinase assays, NLRP3 localization/oligomerization, ASC polymerization, IL-1β assays","pmids":["34554188"],"confidence":"High","gaps":["Stoichiometry of NLRP3 phosphosites in vivo not fully mapped","Relative contribution versus other NLRP3 regulators unclear"]},{"year":2021,"claim":"Demonstrated a receptor-selective platelet role for BTK, essential in CLEC-2 but only modulatory in GPVI signaling, informing inhibitor bleeding risk.","evidence":"Platelet activation/phosphorylation assays, inhibitor dose-response, XLA patient platelets, in vivo thrombosis models","pmids":["31949019"],"confidence":"High","gaps":["Molecular basis of CLEC-2 versus GPVI selectivity not fully defined"]},{"year":2024,"claim":"Showed BTK drives fungus-induced neutrophil oxidative burst via p40phox and RAC2, extending BTK's innate role to antifungal defense.","evidence":"Neutrophil-specific conditional Btk knockout mice, XLA neutrophils, inhibitor studies, p40phox/RAC2 activation assays, aspergillosis models","pmids":["38696257"],"confidence":"High","gaps":["Direct BTK substrate in NADPH oxidase assembly not identified","Pathway from TLR2/Dectin-1/FcγR to BTK not fully mapped"]},{"year":2024,"claim":"Revealed a metabolic role for BTK in macrophage fatty acid oxidation negatively regulated by a TREM2-SHP1 axis during sepsis.","evidence":"Co-IP of TREM2 with SHP1, Trem2 knockout mice, FAO and triglyceride assays, BTK activity assays, survival studies","pmids":["39405126"],"confidence":"Medium","gaps":["Direct BTK substrates in FAO pathway undefined","Single lab"]},{"year":2022,"claim":"Uncovered a kinase-independent BTK scaffold mechanism of drug resistance, with kinase-dead C481F/Y mutants recruiting and activating HCK to sustain PLCγ2 signaling.","evidence":"Kinase assays, structural modeling, co-IP of BTK C481F/Y with HCK, Y551/PLCγ2/NF-κB phosphorylation, clonogenic assays","pmids":["35639855"],"confidence":"High","gaps":["In vivo prevalence of the scaffold mechanism not quantified"]},{"year":2021,"claim":"Identified an alternative resistance route in which RAC2 epigenetically substitutes for BTK in activating PLCγ2/NF-κB.","evidence":"Ibrutinib-resistance modeling in ABC-DLBCL, genetic screens, RAC2/PLCγ2 interaction studies, patient CLL analysis","pmids":["34778802"],"confidence":"Medium","gaps":["Mechanism of TCF4-driven RAC2 induction incompletely defined","Single lab"]},{"year":2020,"claim":"Provided structural insight into BTK-targeting degraders by characterizing ternary complexes with cIAP1, showing complex stability does not predict degradation efficiency.","evidence":"X-ray crystallography of BTK-cIAP1-degrader ternary complexes with degradation assays","pmids":["33199914"],"confidence":"High","gaps":["Determinants of productive degradation beyond stability not fully resolved"]},{"year":2023,"claim":"Validated a noncovalent inhibitor strategy: pirtobrutinib binds outside C481, inhibits C481 mutants, and locks BTK in a closed conformation preventing Y551 phosphorylation.","evidence":"Structural binding studies, enzymatic and cellular assays, differential scanning fluorimetry, Y551 assays, xenografts","pmids":["36796019"],"confidence":"High","gaps":["Does not address kinase-independent scaffold resistance"]},{"year":2024,"claim":"Demonstrated that targeted degradation overcomes both catalytic and scaffold resistance by eliminating all mutant BTK proteoforms, with clinical proof of concept.","evidence":"Mutant enzymatic characterization, interaction studies, proteasomal degradation assays, BCR blockade, CLL patient BTK degradation by NX-2127","pmids":["38301010"],"confidence":"High","gaps":["Durability of clinical response and emergence of degrader resistance not addressed"]},{"year":null,"claim":"How BTK's diverse roles—BCR signaling, inflammasome activation, innate oxidative burst, and macrophage metabolism—are coordinated and which direct substrates operate in each context remains incompletely defined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Comprehensive direct substrate map across cell types lacking","Integration of distinct activation inputs (PIP3, IP6, scaffold) in vivo unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,2,10,12]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,10]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[3]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[8,9]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3,6]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,7,10,15]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,2,11]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[5,9]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[8,12,13]}],"complexes":["NLRP3 inflammasome"],"partners":["SYK","BLNK","PLCG2","HCK","NLRP3","AKT","FAS","PRKD1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q06187","full_name":"Tyrosine-protein kinase BTK","aliases":["Agammaglobulinemia tyrosine kinase","ATK","B-cell progenitor kinase","BPK","Bruton tyrosine kinase"],"length_aa":659,"mass_kda":76.3,"function":"Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling (PubMed:19290921). Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation (PubMed:19290921). After BCR engagement and activation at the plasma membrane, phosphorylates PLCG2 at several sites, igniting the downstream signaling pathway through calcium mobilization, followed by activation of the protein kinase C (PKC) family members (PubMed:11606584). PLCG2 phosphorylation is performed in close cooperation with the adapter protein B-cell linker protein BLNK (PubMed:11606584). BTK acts as a platform to bring together a diverse array of signaling proteins and is implicated in cytokine receptor signaling pathways (PubMed:16517732, PubMed:17932028). Plays an important role in the function of immune cells of innate as well as adaptive immunity, as a component of the Toll-like receptors (TLR) pathway (PubMed:16517732). The TLR pathway acts as a primary surveillance system for the detection of pathogens and are crucial to the activation of host defense (PubMed:16517732). Especially, is a critical molecule in regulating TLR9 activation in splenic B-cells (PubMed:16517732, PubMed:17932028). Within the TLR pathway, induces tyrosine phosphorylation of TIRAP which leads to TIRAP degradation (PubMed:16415872). BTK also plays a critical role in transcription regulation (PubMed:19290921). Induces the activity of NF-kappa-B, which is involved in regulating the expression of hundreds of genes (PubMed:19290921). BTK is involved on the signaling pathway linking TLR8 and TLR9 to NF-kappa-B (PubMed:19290921). Acts as an activator of NLRP3 inflammasome assembly by mediating phosphorylation of NLRP3 (PubMed:34554188). Transiently phosphorylates transcription factor GTF2I on tyrosine residues in response to BCR (PubMed:9012831). GTF2I then translocates to the nucleus to bind regulatory enhancer elements to modulate gene expression (PubMed:9012831). ARID3A and NFAT are other transcriptional target of BTK (PubMed:16738337). BTK is required for the formation of functional ARID3A DNA-binding complexes (PubMed:16738337). There is however no evidence that BTK itself binds directly to DNA (PubMed:16738337). BTK has a dual role in the regulation of apoptosis (PubMed:9751072). Plays a role in STING1-mediated induction of type I interferon (IFN) response by phosphorylating DDX41 (PubMed:25704810)","subcellular_location":"Cytoplasm; Cell membrane; Nucleus; Membrane raft","url":"https://www.uniprot.org/uniprotkb/Q06187/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BTK","classification":"Not Classified","n_dependent_lines":9,"n_total_lines":1208,"dependency_fraction":0.0074503311258278145},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BTK","total_profiled":1310},"omim":[{"mim_id":"621356","title":"SH3 AND CYSTEINE-RICH DOMAINS 2; STAC2","url":"https://www.omim.org/entry/621356"},{"mim_id":"615214","title":"AGAMMAGLOBULINEMIA 7, AUTOSOMAL RECESSIVE; AGM7","url":"https://www.omim.org/entry/615214"},{"mim_id":"608232","title":"LEUKEMIA, CHRONIC MYELOID; CML","url":"https://www.omim.org/entry/608232"},{"mim_id":"606457","title":"INHIBITOR OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE; IBTK","url":"https://www.omim.org/entry/606457"},{"mim_id":"605988","title":"DNA CROSS-LINK REPAIR PROTEIN 1C; DCLRE1C","url":"https://www.omim.org/entry/605988"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":24.2},{"tissue":"lymphoid tissue","ntpm":62.7}],"url":"https://www.proteinatlas.org/search/BTK"},"hgnc":{"alias_symbol":["ATK","XLA","PSCTK1"],"prev_symbol":["AGMX1","IMD1"]},"alphafold":{"accession":"Q06187","domains":[{"cath_id":"2.30.29.30","chopping":"5-166","consensus_level":"high","plddt":86.5294,"start":5,"end":166},{"cath_id":"2.30.30.40","chopping":"217-270","consensus_level":"high","plddt":88.7531,"start":217,"end":270},{"cath_id":"3.30.505.10","chopping":"281-375","consensus_level":"high","plddt":86.8325,"start":281,"end":375},{"cath_id":"3.30.200.20","chopping":"398-474","consensus_level":"high","plddt":88.1227,"start":398,"end":474},{"cath_id":"1.10.510.10","chopping":"479-657","consensus_level":"high","plddt":92.5988,"start":479,"end":657}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q06187","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q06187-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q06187-F1-predicted_aligned_error_v6.png","plddt_mean":84.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BTK","jax_strain_url":"https://www.jax.org/strain/search?query=BTK"},"sequence":{"accession":"Q06187","fasta_url":"https://rest.uniprot.org/uniprotkb/Q06187.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q06187/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q06187"}},"corpus_meta":[{"pmid":"23782157","id":"PMC_23782157","title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.","date":"2013","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23782157","citation_count":1359,"is_preprint":false},{"pmid":"7552994","id":"PMC_7552994","title":"Defective B cell development and function in Btk-deficient mice.","date":"1995","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/7552994","citation_count":601,"is_preprint":false},{"pmid":"28418267","id":"PMC_28418267","title":"BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.","date":"2017","source":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28418267","citation_count":420,"is_preprint":false},{"pmid":"19290921","id":"PMC_19290921","title":"Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain.","date":"2009","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19290921","citation_count":402,"is_preprint":false},{"pmid":"31075187","id":"PMC_31075187","title":"Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.","date":"2019","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31075187","citation_count":252,"is_preprint":false},{"pmid":"33777941","id":"PMC_33777941","title":"Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33777941","citation_count":211,"is_preprint":false},{"pmid":"26957112","id":"PMC_26957112","title":"Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.","date":"2016","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26957112","citation_count":194,"is_preprint":false},{"pmid":"23958373","id":"PMC_23958373","title":"Ibrutinib and novel BTK inhibitors in clinical development.","date":"2013","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23958373","citation_count":188,"is_preprint":false},{"pmid":"14610042","id":"PMC_14610042","title":"The B cell antigen receptor controls integrin activity through Btk and PLCgamma2.","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/14610042","citation_count":187,"is_preprint":false},{"pmid":"37407001","id":"PMC_37407001","title":"Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.","date":"2023","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37407001","citation_count":182,"is_preprint":false},{"pmid":"22449073","id":"PMC_22449073","title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy.","date":"2012","source":"International reviews of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22449073","citation_count":178,"is_preprint":false},{"pmid":"9695187","id":"PMC_9695187","title":"Btk function in B cell development and response.","date":"1998","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9695187","citation_count":154,"is_preprint":false},{"pmid":"38301010","id":"PMC_38301010","title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.","date":"2024","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/38301010","citation_count":119,"is_preprint":false},{"pmid":"35417637","id":"PMC_35417637","title":"Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.","date":"2022","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35417637","citation_count":119,"is_preprint":false},{"pmid":"24603851","id":"PMC_24603851","title":"miR-7 inhibits glioblastoma growth by simultaneously interfering with the PI3K/ATK and Raf/MEK/ERK pathways.","date":"2014","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24603851","citation_count":118,"is_preprint":false},{"pmid":"11226282","id":"PMC_11226282","title":"BLNK mediates Syk-dependent Btk activation.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11226282","citation_count":115,"is_preprint":false},{"pmid":"34803999","id":"PMC_34803999","title":"Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34803999","citation_count":113,"is_preprint":false},{"pmid":"26341110","id":"PMC_26341110","title":"BTK Signaling in B Cell Differentiation and Autoimmunity.","date":"2016","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26341110","citation_count":113,"is_preprint":false},{"pmid":"31028669","id":"PMC_31028669","title":"Targeting BTK in CLL: Beyond Ibrutinib.","date":"2019","source":"Current hematologic malignancy reports","url":"https://pubmed.ncbi.nlm.nih.gov/31028669","citation_count":112,"is_preprint":false},{"pmid":"36796019","id":"PMC_36796019","title":"Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/36796019","citation_count":110,"is_preprint":false},{"pmid":"28641100","id":"PMC_28641100","title":"Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.","date":"2017","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/28641100","citation_count":105,"is_preprint":false},{"pmid":"8520028","id":"PMC_8520028","title":"The Btk subfamily of cytoplasmic tyrosine kinases: structure, regulation and function.","date":"1995","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8520028","citation_count":95,"is_preprint":false},{"pmid":"25699547","id":"PMC_25699547","title":"Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate.","date":"2015","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/25699547","citation_count":93,"is_preprint":false},{"pmid":"9445504","id":"PMC_9445504","title":"Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 unique mutations without correlation to clinical course.","date":"1998","source":"Pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/9445504","citation_count":90,"is_preprint":false},{"pmid":"33199914","id":"PMC_33199914","title":"Snapshots and ensembles of BTK and cIAP1 protein degrader ternary complexes.","date":"2020","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/33199914","citation_count":88,"is_preprint":false},{"pmid":"24357428","id":"PMC_24357428","title":"Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.","date":"2014","source":"Current hematologic malignancy reports","url":"https://pubmed.ncbi.nlm.nih.gov/24357428","citation_count":83,"is_preprint":false},{"pmid":"27641927","id":"PMC_27641927","title":"Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.","date":"2016","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/27641927","citation_count":76,"is_preprint":false},{"pmid":"34276674","id":"PMC_34276674","title":"BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34276674","citation_count":76,"is_preprint":false},{"pmid":"38478390","id":"PMC_38478390","title":"BTK inhibitors in CLL: second-generation drugs and beyond.","date":"2024","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/38478390","citation_count":75,"is_preprint":false},{"pmid":"36287227","id":"PMC_36287227","title":"Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.","date":"2023","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/36287227","citation_count":70,"is_preprint":false},{"pmid":"9751072","id":"PMC_9751072","title":"Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis.","date":"1998","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/9751072","citation_count":69,"is_preprint":false},{"pmid":"34554188","id":"PMC_34554188","title":"BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34554188","citation_count":69,"is_preprint":false},{"pmid":"36696464","id":"PMC_36696464","title":"BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.","date":"2023","source":"Blood advances","url":"https://pubmed.ncbi.nlm.nih.gov/36696464","citation_count":67,"is_preprint":false},{"pmid":"22589540","id":"PMC_22589540","title":"Tyrosine kinase Btk is required for NK cell activation.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22589540","citation_count":63,"is_preprint":false},{"pmid":"38141832","id":"PMC_38141832","title":"BTK signaling-a crucial link in the pathophysiology of chronic spontaneous urticaria.","date":"2023","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38141832","citation_count":61,"is_preprint":false},{"pmid":"8885720","id":"PMC_8885720","title":"X-linked agammaglobulinemia (XLA): a genetic tyrosine kinase (Btk) disease.","date":"1996","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/8885720","citation_count":60,"is_preprint":false},{"pmid":"28901789","id":"PMC_28901789","title":"Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.","date":"2017","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/28901789","citation_count":60,"is_preprint":false},{"pmid":"27157620","id":"PMC_27157620","title":"FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27157620","citation_count":60,"is_preprint":false},{"pmid":"9287186","id":"PMC_9287186","title":"Role of Btk in B cell development and signaling.","date":"1997","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9287186","citation_count":58,"is_preprint":false},{"pmid":"34349760","id":"PMC_34349760","title":"Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34349760","citation_count":54,"is_preprint":false},{"pmid":"34778802","id":"PMC_34778802","title":"Overcoming Acquired Epigenetic Resistance to BTK Inhibitors.","date":"2021","source":"Blood cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34778802","citation_count":54,"is_preprint":false},{"pmid":"33740548","id":"PMC_33740548","title":"Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.","date":"2021","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33740548","citation_count":52,"is_preprint":false},{"pmid":"30888232","id":"PMC_30888232","title":"Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).","date":"2019","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/30888232","citation_count":50,"is_preprint":false},{"pmid":"31949019","id":"PMC_31949019","title":"Low-dose Btk inhibitors selectively block platelet activation by CLEC-2.","date":"2021","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/31949019","citation_count":50,"is_preprint":false},{"pmid":"32401033","id":"PMC_32401033","title":"A Fast and Clean BTK Inhibitor.","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32401033","citation_count":49,"is_preprint":false},{"pmid":"27669440","id":"PMC_27669440","title":"From identification of the BTK kinase to effective management of leukemia.","date":"2016","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/27669440","citation_count":48,"is_preprint":false},{"pmid":"27630139","id":"PMC_27630139","title":"BTK Modulates p53 Activity to Enhance Apoptotic and Senescent Responses.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27630139","citation_count":48,"is_preprint":false},{"pmid":"34299259","id":"PMC_34299259","title":"Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34299259","citation_count":47,"is_preprint":false},{"pmid":"34885993","id":"PMC_34885993","title":"The Development of BTK Inhibitors: A Five-Year Update.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34885993","citation_count":47,"is_preprint":false},{"pmid":"10075013","id":"PMC_10075013","title":"Signalling of Bruton's tyrosine kinase, Btk.","date":"1999","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10075013","citation_count":46,"is_preprint":false},{"pmid":"30706214","id":"PMC_30706214","title":"Development of BTK inhibitors for the treatment of B-cell malignancies.","date":"2019","source":"Archives of pharmacal research","url":"https://pubmed.ncbi.nlm.nih.gov/30706214","citation_count":44,"is_preprint":false},{"pmid":"26821304","id":"PMC_26821304","title":"Btk inhibition treats TLR7/IFN driven murine lupus.","date":"2016","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/26821304","citation_count":43,"is_preprint":false},{"pmid":"11102316","id":"PMC_11102316","title":"Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA).","date":"2000","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/11102316","citation_count":42,"is_preprint":false},{"pmid":"39025681","id":"PMC_39025681","title":"BTK inhibitors: past, present, and future.","date":"2024","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39025681","citation_count":40,"is_preprint":false},{"pmid":"35639855","id":"PMC_35639855","title":"Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK.","date":"2022","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/35639855","citation_count":40,"is_preprint":false},{"pmid":"34509879","id":"PMC_34509879","title":"Discovery of novel BTK PROTACs for B-Cell lymphomas.","date":"2021","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34509879","citation_count":36,"is_preprint":false},{"pmid":"34091303","id":"PMC_34091303","title":"Novel irreversible covalent BTK inhibitors discovered using DNA-encoded chemistry.","date":"2021","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34091303","citation_count":36,"is_preprint":false},{"pmid":"10561498","id":"PMC_10561498","title":"Bruton's tyrosine kinase (Btk) associates with protein kinase C mu.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10561498","citation_count":36,"is_preprint":false},{"pmid":"21518255","id":"PMC_21518255","title":"TEC family kinases in health and disease--loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK.","date":"2011","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/21518255","citation_count":35,"is_preprint":false},{"pmid":"34651869","id":"PMC_34651869","title":"The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.","date":"2021","source":"Hematological oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34651869","citation_count":34,"is_preprint":false},{"pmid":"36402930","id":"PMC_36402930","title":"Managing Waldenström's macroglobulinemia with BTK inhibitors.","date":"2022","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/36402930","citation_count":33,"is_preprint":false},{"pmid":"11213806","id":"PMC_11213806","title":"The cellular phenotype conditions Btk for cell survival or apoptosis signaling.","date":"2000","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/11213806","citation_count":33,"is_preprint":false},{"pmid":"36712232","id":"PMC_36712232","title":"Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development.","date":"2022","source":"Current research in chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/36712232","citation_count":33,"is_preprint":false},{"pmid":"38656399","id":"PMC_38656399","title":"BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair.","date":"2024","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/38656399","citation_count":32,"is_preprint":false},{"pmid":"33718366","id":"PMC_33718366","title":"Targeting the NLRP3 Inflammasome via BTK.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33718366","citation_count":32,"is_preprint":false},{"pmid":"36719376","id":"PMC_36719376","title":"Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.","date":"2023","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/36719376","citation_count":32,"is_preprint":false},{"pmid":"12405164","id":"PMC_12405164","title":"XLA patients with BTK splice-site mutations produce low levels of wild-type BTK transcripts.","date":"2002","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12405164","citation_count":31,"is_preprint":false},{"pmid":"35807447","id":"PMC_35807447","title":"Rutin Inhibits Ox-LDL-Mediated Macrophage Inflammation and Foam Cell Formation by Inducing Autophagy and Modulating PI3K/ATK Signaling.","date":"2022","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35807447","citation_count":30,"is_preprint":false},{"pmid":"34596095","id":"PMC_34596095","title":"COVID-19 and X-linked agammaglobulinemia (XLA) - insights from a monogenic antibody deficiency.","date":"2021","source":"Current opinion in allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34596095","citation_count":29,"is_preprint":false},{"pmid":"31087308","id":"PMC_31087308","title":"Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?","date":"2019","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/31087308","citation_count":29,"is_preprint":false},{"pmid":"38542207","id":"PMC_38542207","title":"Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38542207","citation_count":29,"is_preprint":false},{"pmid":"20634142","id":"PMC_20634142","title":"TLR signaling and effector functions are intact in XLA neutrophils.","date":"2010","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/20634142","citation_count":29,"is_preprint":false},{"pmid":"38696257","id":"PMC_38696257","title":"BTK drives neutrophil activation for sterilizing antifungal immunity.","date":"2024","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38696257","citation_count":28,"is_preprint":false},{"pmid":"39048721","id":"PMC_39048721","title":"Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia.","date":"2024","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/39048721","citation_count":28,"is_preprint":false},{"pmid":"12054657","id":"PMC_12054657","title":"Interaction of Btk and Akt in B cell signaling.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12054657","citation_count":28,"is_preprint":false},{"pmid":"38965189","id":"PMC_38965189","title":"Comparative CNS Pharmacology of the Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib Versus Other BTK Inhibitor Candidates for Treating Multiple Sclerosis.","date":"2024","source":"Drugs in R&D","url":"https://pubmed.ncbi.nlm.nih.gov/38965189","citation_count":27,"is_preprint":false},{"pmid":"35437106","id":"PMC_35437106","title":"Cardiotoxicity of BTK inhibitors: ibrutinib and beyond.","date":"2022","source":"Expert review of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/35437106","citation_count":27,"is_preprint":false},{"pmid":"31397086","id":"PMC_31397086","title":"Effects of BTK signalling in pathogenic microorganism infections.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31397086","citation_count":27,"is_preprint":false},{"pmid":"31819516","id":"PMC_31819516","title":"Long Non-Coding RNA HOTAIR Modulates KLF12 to Regulate Gastric Cancer Progression via PI3K/ATK Signaling Pathway by Sponging miR-618.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31819516","citation_count":25,"is_preprint":false},{"pmid":"32640487","id":"PMC_32640487","title":"BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy.","date":"2020","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/32640487","citation_count":24,"is_preprint":false},{"pmid":"38137005","id":"PMC_38137005","title":"Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/38137005","citation_count":24,"is_preprint":false},{"pmid":"30509085","id":"PMC_30509085","title":"TCF19 enhances cell proliferation in hepatocellular carcinoma by activating the ATK/FOXO1 signaling pathway.","date":"2018","source":"Neoplasma","url":"https://pubmed.ncbi.nlm.nih.gov/30509085","citation_count":24,"is_preprint":false},{"pmid":"35330376","id":"PMC_35330376","title":"Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors.","date":"2022","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35330376","citation_count":23,"is_preprint":false},{"pmid":"30956999","id":"PMC_30956999","title":"Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption.","date":"2019","source":"Bone reports","url":"https://pubmed.ncbi.nlm.nih.gov/30956999","citation_count":23,"is_preprint":false},{"pmid":"38211337","id":"PMC_38211337","title":"How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.","date":"2024","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/38211337","citation_count":21,"is_preprint":false},{"pmid":"33735912","id":"PMC_33735912","title":"MARCKS affects cell motility and response to BTK inhibitors in CLL.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33735912","citation_count":21,"is_preprint":false},{"pmid":"38578606","id":"PMC_38578606","title":"New Means and Challenges in the Targeting of BTK.","date":"2024","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/38578606","citation_count":20,"is_preprint":false},{"pmid":"38597202","id":"PMC_38597202","title":"Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.","date":"2024","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/38597202","citation_count":20,"is_preprint":false},{"pmid":"33937249","id":"PMC_33937249","title":"Targeting Solid Tumors With BTK Inhibitors.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33937249","citation_count":20,"is_preprint":false},{"pmid":"39405126","id":"PMC_39405126","title":"TREM2 aggravates sepsis by inhibiting fatty acid oxidation via the SHP1/BTK axis.","date":"2024","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/39405126","citation_count":19,"is_preprint":false},{"pmid":"36377973","id":"PMC_36377973","title":"BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.","date":"2022","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/36377973","citation_count":19,"is_preprint":false},{"pmid":"15180538","id":"PMC_15180538","title":"Therapeutic potential of inhibiting Bruton's tyrosine kinase, (BTK).","date":"2004","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/15180538","citation_count":19,"is_preprint":false},{"pmid":"39808800","id":"PMC_39808800","title":"Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors.","date":"2025","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/39808800","citation_count":18,"is_preprint":false},{"pmid":"32614787","id":"PMC_32614787","title":"ROR2 knockdown suppresses breast cancer growth through PI3K/ATK signaling.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32614787","citation_count":18,"is_preprint":false},{"pmid":"31843459","id":"PMC_31843459","title":"Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.","date":"2019","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31843459","citation_count":18,"is_preprint":false},{"pmid":"14614849","id":"PMC_14614849","title":"Amplifying Btk's signal.","date":"2003","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/14614849","citation_count":18,"is_preprint":false},{"pmid":"33613931","id":"PMC_33613931","title":"Current and novel BTK inhibitors in Waldenström's macroglobulinemia.","date":"2021","source":"Therapeutic advances in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/33613931","citation_count":18,"is_preprint":false},{"pmid":"9159207","id":"PMC_9159207","title":"BTK, the tyrosine kinase affected in X-linked agammaglobulinemia.","date":"1997","source":"Frontiers in bioscience : a journal and virtual library","url":"https://pubmed.ncbi.nlm.nih.gov/9159207","citation_count":18,"is_preprint":false},{"pmid":"39941922","id":"PMC_39941922","title":"BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL.","date":"2025","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/39941922","citation_count":17,"is_preprint":false},{"pmid":"34599723","id":"PMC_34599723","title":"BTK Inhibitors in Chronic Lymphocytic Leukemia.","date":"2021","source":"Current hematologic malignancy reports","url":"https://pubmed.ncbi.nlm.nih.gov/34599723","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43374,"output_tokens":5640,"usd":0.107361,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14251,"output_tokens":5529,"usd":0.10474,"stage2_stop_reason":"end_turn"},"total_usd":0.212101,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"Btk is required for normal B cell development in mice; targeted mutations eliminating the PH or kinase domain block Btk protein expression and result in reduced mature conventional B cells, severe B1 cell deficiency, serum IgM and IgG3 deficiency, and defective responses to B cell activators and thymus-independent type II antigens, proving that lack of Btk function produces the Xid phenotype.\",\n      \"method\": \"Gene targeting in embryonic stem cells (knockout of PH or kinase domain), RAG2-deficient blastocyst complementation, germline transmission, in vitro B cell activation assays, in vivo immunization\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — clean loss-of-function mouse models with defined cellular phenotypes, replicated across two distinct knockout alleles\",\n      \"pmids\": [\"7552994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"BLNK mediates Syk-dependent BTK activation in BCR signaling: in a reconstitution cell system, coexpression of BLNK allows Syk to phosphorylate Btk on tyrosine 551, enhancing Btk activity. This interaction requires the Btk SH2 domain binding to BLNK, and BCR-induced Btk phosphorylation and activation are significantly reduced in BLNK-deficient or Syk-deficient B cells.\",\n      \"method\": \"Reconstitution cell system (co-expression), site-specific phosphorylation assay (Y551), SH2 domain interaction studies, BLNK-deficient and Syk-deficient B cell analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution experiments combined with domain-specific interaction mapping and validation in knockout B cells\",\n      \"pmids\": [\"11226282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"BCR-controlled integrin alpha4beta1 (VLA-4)-mediated adhesion of B cells to VCAM-1 and fibronectin requires the consecutive activation of Lyn, Syk, PI3K, Btk, PLCgamma2, IP3R-mediated Ca2+ release, and PKC. Btk is positioned between PI3K and PLCgamma2 in this pathway, and Btk is also involved in control of integrin-mediated adhesion of pre-B cells. Cytoskeletal reorganization and integrin clustering are downstream consequences.\",\n      \"method\": \"Biochemical, pharmacological, and genetic dissection; knockout B cells; pharmacological inhibitors; adhesion assays to VCAM-1 and fibronectin\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — combined biochemical, pharmacological, and genetic approaches in multiple B cell models establishing pathway position\",\n      \"pmids\": [\"14610042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BTK adopts an autoinhibited compact conformation similar to inactive c-Src and c-Abl, stabilized by its PH-TH module together with SH2 and SH3 domains. BTK is activated by membranes containing PIP3. Additionally, inositol hexakisphosphate (IP6), a soluble signaling molecule, activates BTK by inducing transient PH-TH dimerization that promotes transphosphorylation of the kinase domains; this IP6-mediated activation is unique to BTK among Tec-family kinases.\",\n      \"method\": \"X-ray crystallography, biochemical autoinhibition assays, lipid-binding assays, in vitro kinase activity assays, mutational analysis, sequence comparisons\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with multiple in vitro biochemical assays and mutagenesis establishing both autoinhibition mechanism and novel IP6-activation mode\",\n      \"pmids\": [\"25699547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Btk constitutively associates with protein kinase C mu (PKCmu) via its PH-TH domain; both the kinase domain and the regulatory C1 region of PKCmu independently bind the Btk PH-TH domain. This interaction is not affected by BCR crosslinking, phorbol ester, or H2O2 stimulation.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, transient overexpression of PKCmu deletion mutants and domain constructs in 293T cells\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP and GST pulldown with domain mapping in transfected cells, single lab, two orthogonal methods\",\n      \"pmids\": [\"10561498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"BTK functions as a dual-function regulator of apoptosis: it promotes radiation-induced apoptosis (at least partly by down-regulating anti-apoptotic STAT-3 activity in response to reactive oxygen species) but inhibits Fas-activated apoptosis by associating with the death receptor Fas and impairing its interaction with FADD, thereby preventing assembly of the pro-apoptotic DISC.\",\n      \"method\": \"Co-immunoprecipitation (BTK with Fas), functional apoptosis assays (radiation, Fas ligation), STAT-3 activity measurement\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP and functional apoptosis assays, single lab, two orthogonal methods supporting dual role\",\n      \"pmids\": [\"9751072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Endogenous Btk and Akt physically interact in B cells (DT40 chicken B cells and human Nalm6 B cells) and this interaction is inducible by H2O2 stimulation. PI3K and Btk are involved in Akt phosphorylation following H2O2. Btk and Akt co-localize in the perinuclear region and membrane ruffles in COS-7 cells. Btk positively modulates both ERK and JNK phosphorylation downstream of PI3K.\",\n      \"method\": \"Co-immunoprecipitation of endogenous proteins, immunofluorescence co-localization, kinase phosphorylation assays, PI3K inhibitor studies\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — reciprocal co-IP of endogenous proteins with co-localization validation, single lab\",\n      \"pmids\": [\"12054657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Btk is required for NK cell activation: Btk-deficient murine NK cells have decreased innate immune responses to the TLR3 ligand poly(I:C), with reduced IFN-γ, perforin, and granzyme-B expression and decreased cytotoxic activity. Btk promotes TLR3-triggered NK cell activation mainly by activating the NF-κB pathway. XLA patients with BTK deficiency also show reduced TLR3-triggered human NK cell activation.\",\n      \"method\": \"Btk-/- mouse NK cell functional assays, NF-κB pathway analysis, Btk inhibitor in vivo administration, adoptive transfer experiments, XLA patient NK cell assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout mouse model, pharmacological inhibition, adoptive transfer, and human patient validation, multiple orthogonal methods\",\n      \"pmids\": [\"22589540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BTK transcriptionally upregulates BCL2 expression in mantle cell lymphoma through canonical NF-κB activation. BTK knockdown (by shRNA) downregulates a set of anti-apoptotic and proliferative genes including BCL2, BCL-XL, DAD1, BCL6, MYC, PIK3CA, and BAFF-R, as confirmed by RNA-seq analysis.\",\n      \"method\": \"BTK shRNA knockdown, RNA-seq, NF-κB reporter assays, tissue microarray correlation, in vitro and in vivo drug combination studies\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — shRNA knockdown with RNA-seq validation and mechanistic pathway confirmation, single lab\",\n      \"pmids\": [\"27157620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BTK is a novel modulator of p53: BTK is induced in response to DNA damage and p53 activation, and BTK induction leads to p53 phosphorylation, establishing a positive feedback loop that increases p53 protein levels and enhances transactivation of p53 target genes. Inhibiting BTK reduced p53-dependent senescence and apoptosis.\",\n      \"method\": \"BTK induction by DNA damage, BTK inhibitor treatment, p53 phosphorylation assays, senescence and apoptosis functional assays, gene expression analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition and overexpression with functional readouts (senescence, apoptosis) and molecular (p53 phosphorylation), single lab\",\n      \"pmids\": [\"27630139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BTK directly interacts with NLRP3 in immune cells and phosphorylates four conserved tyrosine residues on NLRP3 upon inflammasome activation (demonstrated in vitro and in vivo). BTK promotes NLRP3 relocalization, oligomerization, ASC polymerization, and full inflammasome assembly, likely through charge neutralization upon modification of a polybasic linker that directs NLRP3 Golgi association. BTK-mediated NLRP3 tyrosine phosphorylation positively regulates IL-1β release.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, in vivo phosphorylation assay, NLRP3 localization studies, inflammasome assembly assays (ASC polymerization, oligomerization), IL-1β release measurement\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay plus in vivo validation, direct protein interaction, and multiple functional readouts (localization, oligomerization, IL-1β) in one study\",\n      \"pmids\": [\"34554188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Low concentrations of BTK inhibitor ibrutinib (and acalabrutinib) selectively block CLEC-2-mediated platelet activation and tyrosine phosphorylation (including Syk and PLCγ2) in human platelets. BTK-deficient XLA patients also show abolished CLEC-2-mediated platelet activation. In contrast, GPVI-mediated platelet responses are only delayed (not abolished) at low inhibitor concentrations, with Syk phosphorylation preserved. This differential reflects a positive feedback role for Btk (along with ADP and thromboxane A2 via P2Y12 and TP receptors) that is present in CLEC-2 but not GPVI signaling in human platelets.\",\n      \"method\": \"Platelet activation assays (aggregation, tyrosine phosphorylation), BTK inhibitor dose-response studies, XLA patient platelet studies, in vivo thrombosis models in mice\",\n      \"journal\": \"Haematologica\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human patient (XLA) validation combined with pharmacological inhibition and in vivo mouse model, multiple orthogonal methods\",\n      \"pmids\": [\"31949019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Kinase-dead BTK mutations C481F and C481Y confer ibrutinib resistance through a kinase-independent scaffold mechanism: upon BCR activation, BTK C481F/Y is phosphorylated at Y551 by Src family kinases, which then recruits HCK via its SH2 domain. Structural modeling suggests this binding disrupts an intramolecular autoinhibitory interaction in HCK, activating it. Activated HCK then phosphorylates PLCγ2, propagating BCR signaling and promoting clonogenic cell proliferation despite absence of BTK kinase activity.\",\n      \"method\": \"In vitro kinase assays (confirming loss of kinase activity), structural modeling, co-immunoprecipitation (BTK C481F/Y with HCK), phosphorylation assays (Y551, PLCγ2, NF-κB), clonogenic proliferation assays\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro kinase assays, structural modeling, co-IP, and multiple phosphorylation/functional readouts establishing kinase-independent scaffold mechanism\",\n      \"pmids\": [\"35639855\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Certain drug-resistant BTK mutations (including kinase-impaired forms) acquire novel protein-protein interactions that sustain BCR signaling independently of BTK enzymatic activity (oncogenic scaffold function). The BTK/IKZF1/3 degrader NX-2127 can bind and proteasomally degrade each mutant BTK proteoform, resulting in potent blockade of BCR signaling. Treatment of CLL patients with NX-2127 achieves >80% degradation of BTK.\",\n      \"method\": \"Enzymatic activity characterization of mutant BTK, protein-protein interaction studies, proteasomal degradation assays, BCR signaling blockade assays, clinical BTK degradation measurement\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — biochemical characterization of mutant enzymatic activities, interaction studies, degradation assays, and clinical proof-of-concept in patients\",\n      \"pmids\": [\"38301010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Pirtobrutinib, a noncovalent BTK inhibitor, binds BTK with an extensive network of interactions to BTK and water molecules in the ATP-binding region with no direct interaction with C481, inhibiting both BTK and BTK C481 substitution mutants with similar potencies. Pirtobrutinib stabilizes BTK in a closed, inactive conformation (higher melting temperature than covalent BTKi-bound BTK in differential scanning fluorimetry) and prevents Y551 phosphorylation in the activation loop, unlike covalent BTKis.\",\n      \"method\": \"Structural studies (binding mode characterization), enzymatic assays, cell-based assays, differential scanning fluorimetry, Y551 phosphorylation assays, xenograft tumor growth studies\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural characterization with enzymatic, biophysical, and cellular validation across multiple orthogonal methods\",\n      \"pmids\": [\"36796019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BTK is activated in human neutrophils upon fungal (Aspergillus) exposure in a TLR2-, Dectin-1-, and FcγR-dependent manner, triggering the oxidative burst. BTK inhibition selectively impaired neutrophil-mediated damage to Aspergillus hyphae, primary granule release, and the fungus-induced oxidative burst by abrogating NADPH oxidase subunit p40phox and GTPase RAC2 activation. Neutrophil-specific Btk deletion in mice enhanced aspergillosis susceptibility by impairing neutrophil function without affecting recruitment or lifespan.\",\n      \"method\": \"BTK activation assays in human neutrophils, BTK inhibitor studies, XLA patient neutrophil studies, neutrophil-specific Btk conditional knockout mice, p40phox and RAC2 activation assays, oxidative burst measurements, in vivo aspergillosis models\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — neutrophil-specific conditional KO mice, human patient (XLA) validation, pharmacological inhibition, and molecular mechanism (p40phox, RAC2) established\",\n      \"pmids\": [\"38696257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In diffuse large B-cell lymphoma, acquired resistance to BTK inhibitor ibrutinib is epigenetically driven (in part by transcription factor TCF4), causing a phenotypic shift where GTPase RAC2 substitutes for BTK in the activation of PLCγ2 to sustain NF-κB activity. This RAC2-PLCγ2 interaction was also increased in CLL cells from patients with persistent or progressive disease on BTK inhibitor treatment.\",\n      \"method\": \"Ibrutinib resistance modeling in ABC-DLBCL cells, RNAi/genetic screens, RAC2 overexpression, PLCγ2 interaction studies, NF-κB reporter assays, patient CLL cell analysis\",\n      \"journal\": \"Blood cancer discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro resistance model with molecular pathway identification and human patient validation, single lab\",\n      \"pmids\": [\"34778802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Ternary complex structures of BTK with the E3 ubiquitin ligase cIAP1 and bifunctional degrader compounds were characterized. Increased ternary complex stability or rigidity does not always correlate with increased degradation efficiency.\",\n      \"method\": \"Biochemical, biophysical, and structural studies (X-ray crystallography of ternary complexes), degradation efficiency assays\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures of ternary complexes with biochemical validation, single lab but rigorous methods\",\n      \"pmids\": [\"33199914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TREM2 interacts with the phosphatase SHP1 to inhibit BTK-mediated fatty acid oxidation (FAO) in macrophages during sepsis. TREM2 deficiency in macrophages led to enhanced BTK-mediated FAO, reduced triglyceride accumulation, and improved sepsis outcomes; blockade of FAO abolished these protective effects.\",\n      \"method\": \"Co-immunoprecipitation (TREM2 with SHP1), Trem2 knockout mice, FAO rate measurement, triglyceride accumulation assays, BTK activity assays, survival studies\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP interaction, knockout model, and functional FAO assays, single lab\",\n      \"pmids\": [\"39405126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"BTK activates phosphatidylinositol-4-phosphate 5-kinase (PIP5K) downstream of BCR signaling, generating PI(4,5)P2 which serves as substrate for both PI3K and PLCγ, creating a positive feedback loop that amplifies BTK's signal.\",\n      \"method\": \"Review/commentary citing experimental data (Saito et al.) showing BTK-PIP5K activation and PI(4,5)P2 generation\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — described in a commentary referencing primary data; mechanistic claim supported by cited experimental work but this abstract does not provide direct experimental details\",\n      \"pmids\": [\"14614849\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BTK is a cytoplasmic Tec-family tyrosine kinase that is autoinhibited in a compact conformation (stabilized by PH-TH, SH2, and SH3 domains) and is activated downstream of BCR engagement via sequential Lyn-mediated phosphorylation at Y551 (facilitated by BLNK-scaffolded Syk), and also by PIP3-containing membranes or IP6-induced PH-TH dimerization; once active, BTK phosphorylates PLCγ2 to drive Ca2+ flux, NF-κB, and NFAT signaling, regulates integrin-mediated adhesion, directly phosphorylates and activates the NLRP3 inflammasome, modulates p53-dependent apoptosis/senescence, and in innate immune cells (NK cells, neutrophils) promotes TLR- and pattern-recognition receptor-triggered oxidative burst and cytokine production; drug-resistant kinase-dead BTK mutants can act as scaffolds recruiting and activating HCK to sustain BCR signaling independently of BTK kinase activity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BTK is a cytoplasmic Tec-family tyrosine kinase that transduces B-cell receptor (BCR) signaling and is essential for normal B-cell development, its loss producing the murine Xid phenotype with B1-cell deficiency and impaired antibody responses [#0]. The protein is held in an autoinhibited compact conformation stabilized by its PH-TH module together with the SH2 and SH3 domains, and is activated either at PIP3-containing membranes or, uniquely among Tec kinases, by inositol hexakisphosphate (IP6) that drives transient PH-TH dimerization and kinase transphosphorylation [#3]. Within the BCR pathway, BLNK scaffolds Syk to phosphorylate BTK on Y551 via the BTK SH2 domain, and BCR-induced BTK activation is lost in BLNK- or Syk-deficient B cells [#1]; downstream BTK occupies a position between PI3K and PLCγ2, where it controls integrin α4β1-mediated adhesion through PLCγ2/IP3R-driven Ca2+ release and cytoskeletal reorganization [#2]. Through canonical NF-κB activation BTK drives transcription of anti-apoptotic and proliferative genes including BCL2 in mantle cell lymphoma [#8], and it acts as a direct kinase of the NLRP3 inflammasome, phosphorylating conserved tyrosines to promote NLRP3 relocalization, oligomerization, ASC polymerization and IL-1β release [#10]. BTK function extends to innate immunity, where it is required for TLR3-triggered NK-cell activation via NF-κB [#7] and for fungus-induced neutrophil oxidative burst through p40phox and RAC2 activation [#15]. Clinically important resistance to covalent BTK inhibitors arises through kinase-dead C481 scaffold mutants that recruit and activate HCK to sustain PLCγ2 signaling independently of BTK catalytic activity [#12], a liability addressed by noncovalent inhibitors that bind outside C481 and lock BTK in a closed conformation [#14] and by degraders that eliminate all mutant proteoforms [#13].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established that BTK is genetically required for B-cell development, defining the loss-of-function phenotype and linking the gene to humoral immunodeficiency.\",\n      \"evidence\": \"Targeted knockout of PH or kinase domain in mice with B-cell activation and immunization assays\",\n      \"pmids\": [\"7552994\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not resolve the biochemical signaling step BTK occupies\", \"Phenotype defined in mouse; human XLA correspondence inferred\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identified a constitutive PH-TH-mediated association between BTK and PKCmu, an early clue to BTK's protein interaction surface.\",\n      \"evidence\": \"Co-IP and GST pulldown with PKCmu domain constructs in 293T cells\",\n      \"pmids\": [\"10561498\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of the interaction undefined\", \"Overexpression in transfected cells, single lab\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Placed BTK activation within the BCR proximal cascade by showing BLNK scaffolds Syk to phosphorylate BTK on Y551, resolving how upstream kinases engage BTK.\",\n      \"evidence\": \"Reconstitution co-expression, Y551 phosphorylation assay, SH2 interaction mapping, BLNK/Syk-deficient B cells\",\n      \"pmids\": [\"11226282\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address membrane recruitment via PH domain\", \"Y551 dynamics under physiological BCR engagement not quantified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Positioned BTK between PI3K and PLCγ2 in integrin signaling, extending its role beyond Ca2+ flux to adhesion and cytoskeletal control.\",\n      \"evidence\": \"Genetic and pharmacological dissection of VLA-4-mediated B-cell adhesion to VCAM-1/fibronectin\",\n      \"pmids\": [\"14610042\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct BTK substrates in the adhesion pathway not pinpointed\", \"Pre-B versus mature B-cell contributions only partially separated\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Proposed a positive feedback loop in which BTK activates PIP5K to generate PI(4,5)P2 amplifying its own signal.\",\n      \"evidence\": \"Commentary citing primary BTK-PIP5K activation data\",\n      \"pmids\": [\"14614849\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Claim drawn from a commentary, not direct experimental detail in this entry\", \"Feedback stoichiometry and physiological relevance unquantified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Linked BTK to Akt/ERK/JNK signaling and oxidative stress responses, broadening BTK's downstream signaling reach.\",\n      \"evidence\": \"Reciprocal co-IP of endogenous BTK and Akt, co-localization, kinase assays with PI3K inhibitors in B-cell lines\",\n      \"pmids\": [\"12054657\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect BTK-Akt interaction not distinguished\", \"Single lab without genetic confirmation of the kinase relationships\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Implicated BTK as a bidirectional regulator of apoptosis, promoting radiation-induced death yet inhibiting Fas-DISC assembly.\",\n      \"evidence\": \"Co-IP of BTK with Fas, radiation and Fas-ligation apoptosis assays, STAT-3 activity measurement\",\n      \"pmids\": [\"9751072\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of dual role not reconciled\", \"Single lab, two orthogonal methods\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Extended BTK function to innate immunity by showing it is required for TLR3-triggered NK-cell activation through NF-κB.\",\n      \"evidence\": \"Btk-/- mouse NK-cell assays, NF-κB analysis, adoptive transfer, XLA patient NK cells\",\n      \"pmids\": [\"22589540\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct BTK substrates in TLR3-NK signaling not identified\", \"Mechanism of TLR3-to-BTK coupling unresolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined the structural basis of BTK autoinhibition and revealed a BTK-unique IP6-induced PH-TH dimerization activation mode, resolving how BTK is switched on.\",\n      \"evidence\": \"X-ray crystallography, lipid-binding and kinase assays, mutagenesis, sequence comparisons\",\n      \"pmids\": [\"25699547\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular concentration thresholds for IP6 activation not established\", \"Integration of IP6 and PIP3 activation in vivo unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Connected BTK to a pro-survival transcriptional program, showing it upregulates BCL2 and other anti-apoptotic/proliferative genes via NF-κB in lymphoma.\",\n      \"evidence\": \"shRNA knockdown with RNA-seq, NF-κB reporter assays, tissue microarray in mantle cell lymphoma\",\n      \"pmids\": [\"27157620\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect transcriptional effects not separated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified BTK as a p53 modulator forming a DNA-damage-induced positive feedback loop that enhances p53-dependent senescence and apoptosis.\",\n      \"evidence\": \"BTK induction by DNA damage, inhibitor treatment, p53 phosphorylation and functional senescence/apoptosis assays\",\n      \"pmids\": [\"27630139\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct kinase relationship to p53 not biochemically defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established BTK as a direct NLRP3 kinase, phosphorylating conserved tyrosines to drive inflammasome assembly and IL-1β release.\",\n      \"evidence\": \"Co-IP, in vitro and in vivo kinase assays, NLRP3 localization/oligomerization, ASC polymerization, IL-1β assays\",\n      \"pmids\": [\"34554188\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of NLRP3 phosphosites in vivo not fully mapped\", \"Relative contribution versus other NLRP3 regulators unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated a receptor-selective platelet role for BTK, essential in CLEC-2 but only modulatory in GPVI signaling, informing inhibitor bleeding risk.\",\n      \"evidence\": \"Platelet activation/phosphorylation assays, inhibitor dose-response, XLA patient platelets, in vivo thrombosis models\",\n      \"pmids\": [\"31949019\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of CLEC-2 versus GPVI selectivity not fully defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed BTK drives fungus-induced neutrophil oxidative burst via p40phox and RAC2, extending BTK's innate role to antifungal defense.\",\n      \"evidence\": \"Neutrophil-specific conditional Btk knockout mice, XLA neutrophils, inhibitor studies, p40phox/RAC2 activation assays, aspergillosis models\",\n      \"pmids\": [\"38696257\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct BTK substrate in NADPH oxidase assembly not identified\", \"Pathway from TLR2/Dectin-1/FcγR to BTK not fully mapped\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Revealed a metabolic role for BTK in macrophage fatty acid oxidation negatively regulated by a TREM2-SHP1 axis during sepsis.\",\n      \"evidence\": \"Co-IP of TREM2 with SHP1, Trem2 knockout mice, FAO and triglyceride assays, BTK activity assays, survival studies\",\n      \"pmids\": [\"39405126\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct BTK substrates in FAO pathway undefined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Uncovered a kinase-independent BTK scaffold mechanism of drug resistance, with kinase-dead C481F/Y mutants recruiting and activating HCK to sustain PLCγ2 signaling.\",\n      \"evidence\": \"Kinase assays, structural modeling, co-IP of BTK C481F/Y with HCK, Y551/PLCγ2/NF-κB phosphorylation, clonogenic assays\",\n      \"pmids\": [\"35639855\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo prevalence of the scaffold mechanism not quantified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified an alternative resistance route in which RAC2 epigenetically substitutes for BTK in activating PLCγ2/NF-κB.\",\n      \"evidence\": \"Ibrutinib-resistance modeling in ABC-DLBCL, genetic screens, RAC2/PLCγ2 interaction studies, patient CLL analysis\",\n      \"pmids\": [\"34778802\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of TCF4-driven RAC2 induction incompletely defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Provided structural insight into BTK-targeting degraders by characterizing ternary complexes with cIAP1, showing complex stability does not predict degradation efficiency.\",\n      \"evidence\": \"X-ray crystallography of BTK-cIAP1-degrader ternary complexes with degradation assays\",\n      \"pmids\": [\"33199914\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of productive degradation beyond stability not fully resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Validated a noncovalent inhibitor strategy: pirtobrutinib binds outside C481, inhibits C481 mutants, and locks BTK in a closed conformation preventing Y551 phosphorylation.\",\n      \"evidence\": \"Structural binding studies, enzymatic and cellular assays, differential scanning fluorimetry, Y551 assays, xenografts\",\n      \"pmids\": [\"36796019\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not address kinase-independent scaffold resistance\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated that targeted degradation overcomes both catalytic and scaffold resistance by eliminating all mutant BTK proteoforms, with clinical proof of concept.\",\n      \"evidence\": \"Mutant enzymatic characterization, interaction studies, proteasomal degradation assays, BCR blockade, CLL patient BTK degradation by NX-2127\",\n      \"pmids\": [\"38301010\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Durability of clinical response and emergence of degrader resistance not addressed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BTK's diverse roles—BCR signaling, inflammasome activation, innate oxidative burst, and macrophage metabolism—are coordinated and which direct substrates operate in each context remains incompletely defined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Comprehensive direct substrate map across cell types lacking\", \"Integration of distinct activation inputs (PIP3, IP6, scaffold) in vivo unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 2, 10, 12]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 10]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [8, 9]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 6]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 7, 10, 15]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 2, 11]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [5, 9]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8, 12, 13]}\n    ],\n    \"complexes\": [\"NLRP3 inflammasome\"],\n    \"partners\": [\"SYK\", \"BLNK\", \"PLCG2\", \"HCK\", \"NLRP3\", \"AKT\", \"FAS\", \"PRKD1\"]\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}